Provided by Johns Hopkins University School of Medicine
In Cooperation With
Medical Logix, LLC.
This activity is supported by educational grants from Biogen and Novartis.
Despite decades of progress in the management of relapsing-remitting multiple sclerosis (RRMS), notable challenges remain. With a growing armamentarium of treatment options, clinicians are faced with the need to understand the full range of risk-benefit profiles so as to select the most appropriate therapy based on individual patient characteristics. Of particular concern are the large numbers of patients who fail to respond adequately to initial treatment with a disease-modifying therapy (DMT). Prompt recognition of such patients is crucial to prevent the accumulation of disability and delay disease progression. Clinicians must have the requisite knowledge to identify clinical and MRI findings suggestive of a suboptimal response that necessitates switching to another treatment strategy. The process of deciding which DMT should be chosen when switching therapy mandates consideration of the mode of actions, efficacy and safety, and individual patient factors. Clinicians must be competent in addressing these issues if the best possible outcomes are to be achieved. The potential advent of additional treatments also highlights the need for clinicians to stay up to date on developments that may impact the management of RRMS in the future.
This initiative is intended to meet the educational needs of neurologists and other healthcare practitioners involved in the care of patients with multiple sclerosis.
Upon completion of this educational activity, participants should be able to:
Explain the mechanisms of action of available and emerging multiple sclerosis (MS) therapies as well as implications for treatment selection
Discuss the efficacy and safety of current treatments for MS and available data on investigational therapies
Review perspectives on MRI and clinical findings that may prompt consideration of switching therapy for MS
Analyze knowledge about MS therapies and aspects of a patient’s presentation to make an informed decision when switching MS therapies
Conflict Of Interest Disclosure Policy
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the instructional materials.
The faculty reported any relationships for this activity under the Faculty heading below.
Johns Hopkins Chair and Activity Director Shiv Saidha, MBBCh, MD, MRCPI Associate Professor of Neurology Division of Neuroimmunology and Neurological Infections Johns Hopkins University School of Medicine Baltimore, MD
Dr. Saidha discloses the following: Contracted Research: Genentech, Inc. Consulting Fee: Biogen Idec, EMD Serono, Genzyme Corporation, Novartis AG Equity: 2% JuneBrain
Faculty Robert Bermel, MD Assistant Professor of Medicine Case Western Reserve University, School of Medicine Director, Mellen Center for Multiple Sclerosis Cleveland Clinic Neurological Institute Cleveland, OH
Dr. Bermel discloses the following: Contracted Research: Biogen Idec Consulting Fee: Genentech, Inc., Genzyme Corporation, Novartis AG
Scott Newsome, DO, MSCS, FAAN Associate Professor of Neurology Director, Neurology Outpatient Services Director, Neurology Infusion Center Director, Stiff Person Syndrome Center Member, Miller-Coulson Academy of Clinical Excellence Division of Neuroimmunology and Neuroinfectious Diseases Johns Hopkins University School of Medicine Baltimore, MD
Dr. Newsome discloses the following: Contracted Research: Biogen Idec, Genentech, Inc., Novartis AG Consulting Fee: Biogen Idec, Celgene, Genentech Inc.
Publishing Staff Disclosures
Michael Speidel and Joanne Jeffers, Medical Logix, LLC, and Nancy Baxter, Baxter Medical Communications, have no relationship with any commercial interests whose products or services may be mentioned during this presentation.
AMA PRA Category 1 Credit(s)TM
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
American Association of Nurse Practitioners (AANP) National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the ACCME. PAs may receive a maximum of 1.75 AAPA Category 1 Credits for completing this program.
Johns Hopkins Statement of Responsibility
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
Disclosure of Unlabeled Use
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
Robert Bermel, MD, Scott Newsome, DO, and Shiv Saidha, MBBCh, MD: cladribine, high-dose biotin, ofatumumab, opicinumab, ponesimod, siponimod
Internet CME Policy
The Office of Continuing Medical Education (OCME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University School of Medicine OCME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. OCME at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine CME program. CME collects only the information necessary to provide you with the services that you request.
The opinions and recommendations expressed by faculty and other experts, whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For CME Questions, please contact the CME Office (410) 955-2959 or e-mail firstname.lastname@example.org.
NOTE: Please complete the Clinical Dialogue and the eCase Challenge before clicking the Post-Test button in order to claim full credit of this activity.
Americans with Disabilities Act
The Johns Hopkins University School of Medicine fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.
Confidentiality Disclaimer for CME Activity Participants
I certify that I am participating in a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.
I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person.
I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (e.g. Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.
I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.
“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.”
Johns Hopkins University School of Medicine Office of Continuing Medical Education Turner 20/720 Rutland Avenue Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)